J&J's BC­MA/CD3 bis­pe­cif­ic nabs a con­di­tion­al EMA nod, jump­ing in front of FDA

The Eu­ro­pean Med­i­cines Agency (EMA) has rec­om­mend­ed a con­di­tion­al mar­ket­ing au­tho­riza­tion for J&J’s mul­ti­ple myelo­ma drug teclis­tam­ab, a BC­MA/CD3 bis­pe­cif­ic an­ti­body, which hasn’t been FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER